AZD1613 - Part A + Placebo - Part A + AZD1613 - Part B + Placebo - Part B

Phase 1Recruiting

1 views this week 0 watching💤 Quiet

Interest: 36/100

Hype Score

Development Stage

✓

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Autosomal Dominant Polycystic Kidney Disease

Conditions

Autosomal Dominant Polycystic Kidney Disease

Trial Timeline

Nov 10, 2025 → Jan 4, 2027

NCT ID

NCT07228364

About AZD1613 - Part A + Placebo - Part A + AZD1613 - Part B + Placebo - Part B

AZD1613 - Part A + Placebo - Part A + AZD1613 - Part B + Placebo - Part B is a phase 1 stage product being developed by AstraZeneca for Autosomal Dominant Polycystic Kidney Disease. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07228364. Target conditions include Autosomal Dominant Polycystic Kidney Disease.

What happened to similar drugs?

1 of 5 similar drugs in Autosomal Dominant Polycystic Kidney Disease were approved

Approved (1) Terminated (2) Active (2)

✅Placebo + EverolimusNovartisApproved

🔄Everolimus + Calcineurin inhibitors maintenanceNovartisPhase 3

❌Bardoxolone methyl oral capsule + Placebo oral capsuleBiogenPhase 3

🔄Lanreotide + salineIpsenPhase 3

❌Lixivaptan + PlaceboCentessa PharmaceuticalsPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT07228364	Phase 1	Recruiting	Nov 10, 2025	Jan 4, 2027	Autosomal Dominant Polycystic Kidney Disease

Competing Products

19 competing products in Autosomal Dominant Polycystic Kidney Disease

See all competitors

Product	Company	Stage	Hype Score
ABBV-CLS-628 + Placebo	AbbVie	Phase 2	42
Placebo + Everolimus	Novartis	Approved	43
Octreotide + Placebo	Novartis	Phase 2/3	38
Everolimus + Calcineurin inhibitors maintenance	Novartis	Phase 3	40
Bosutinib + Bosutinib + Placebo	Pfizer	Phase 2	35
VX-407	Vertex Pharmaceuticals	Phase 2	42
VX-407 + LNG/EE + NGM/EE + NET/EE + DRSP/EE	Vertex Pharmaceuticals	Phase 1	33
VX-407 + Placebo + Midazolam + VX-407	Vertex Pharmaceuticals	Phase 1	29
VX-407 + Placebo	Vertex Pharmaceuticals	Phase 1	33
Tesevatinib	Sanofi	Phase 1/2	32
Tesevatinib + Placebo	Sanofi	Phase 2	35
Venglustat + Placebo	Sanofi	Phase 2/3	30
Bardoxolone methyl oral capsule + Placebo oral capsule	Biogen	Phase 3	29
Lanreotide + saline	Ipsen	Phase 3	37
KB105	Krystal Biotech	Phase 2	28
KB105	Krystal Biotech	Phase 1/2	25
Lixivaptan + Placebo	Centessa Pharmaceuticals	Phase 3	29
GLPG2737 + Placebo	Galapagos	Phase 2	21
QR-1123	ProQR	Phase 1/2	26